Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNJLW2)

Drug Name

NSC-645827 Drug Info

Synonyms

NSC-645827; MLS002701557; C 1303; 128113-19-9; NSC645827; AC1L3YJ7; CHEMBL95704; DTXSID30155810; ZINC5140451; 5-(2-(Diethylamino)ethylamino)-8-hydroxy-6H-(1,2,3)triazolo(4,5-1-de)acridin-6-one; SMR001565158; NCI60_015716; 5-[2-Dimethylaminoethylamino]-8-hydroxy-6H-[1,2,3]triazolo[4,5,1-de]acridin-6-one; 5-(2-(dimethylamino)ethylamino)-8-hydroxy-6H-[1,3]triazolo[4,5,1-de]acridin-6-one; 6H-(1,2,3)Triazolo(4,5,1-de)acridin-6-one, 5-((2-(dimethylamino)ethyl)amino)-8-hydroxy-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 124496
CAS Number: CAS 128113-19-9
TTD Drug ID: DMNJLW2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Quinone reductase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ 761	DMH5CAL	Pancreatic cancer	2C10	Phase 2	[2]
Coenzyme Q10 analog	DMO0VGH	Huntington disease	8A01.10	Phase 2	[3]
BioE-743	DM7PT8R	Leigh syndrome	5C53.24	Phase 2	[4]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[5]
NSC-645808	DMMBAR3	Discovery agent	N.A.	Investigative	[1]
NSC-106080	DMR6P9S	Discovery agent	N.A.	Investigative	[6]
NSC-99528	DMXZAIG	Discovery agent	N.A.	Investigative	[6]
NSC-354279	DMVL51I	Discovery agent	N.A.	Investigative	[1]
Duroquinone	DML7YPS	Discovery agent	N.A.	Investigative	[5]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate	DMJQTIK	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Quinone reductase 1 (NQO1)	TT8XK6L	NQO1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
7	Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.